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Background: Ovarian cancer is the most deadly gynecological cancer due to late diagnosis at advanced stage with
major peritoneal involvement. To date most research has focused on primary tumor. However the prognosis is
directly related to residual disease at the end of the treatment. Therefore it is mandatory to focus and study the
biology of meatastatic disease that is most frequently localized to the peritoneal caivty in ovarian cancer.
Methods: We used high-density gene expression arrays to investigate gene expression changes between matched
primary and metastatic (peritoneal) lesions.
Results: Here we show that gene expression profiles in peritoneal metastasis are significantly different than their
matched primary tumor and these changes are affected by underlying copy number variation differences among
other causes. We show that differentially expressed genes are enriched in specific pathways including JAK/STAT
pathway, cytokine signaling and other immune related pathways. We show that underlying copy number variations
significantly affect gene expression. Indeed patients with important differences in copy number variation displayed
greater gene expression differences between their primary and matched metastatic lesions.
Conclusions: Our analysis shows a very specific targeting at both the genomic and transcriptomic level to
upregulate certain pathways in the peritoneal metastasis of ovarian cancer. Moreover, while primary tumors use
certain pathways we identify distinct differences with metastatic lesions. The variation between primary and
metastatic lesions should be considered in personalized treatment of ovarian cancer.Background
Epithelial Ovarian carcinoma (EOC) is the sixth most
common malignancy in women and the leading cause of
death from gynecological cancer [1]. The poor overall
survival (20 to 30% at 5 years) is due to large tumor bur-
den with extensive peritoneal metastatic lesions. Abdom-
inal recurrences remain an issue and result in patients’
poor prognosis despite ultra-radical surgical procedures
and initial chemosensitivity. Advanced ovarian cancer
therefore represents a unique situation with most pa-
tients having progressed to the metastatic stage but the
treatment still aims at cure. The high rate of peritoneal
recurrences after debulking surgery and chemotherapy* Correspondence: jat2021@qatar-med.cornell.edu
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reproduction in any medium, provided the orindicates our failure to correctly target the metastatic
lesions. Indeed it has been demonstrated that peritoneal
residual disease (even below 5 mm) impacts prognosis
[2]. This has led to a change of practice with a combin-
ation of ultra-radical surgeries and chemotherapy to
achieve complete (no macroscopic) tumor residue.
Therefore with the advent of personalized medicine it
is critical to understand the molecular pathways under-
lying peritoneal metastasis in order to be able to define
new therapeutic strategies. This will require understand-
ing the genetic variation in both primary and metastatic
lesions to correctly optimize the therapy on an individual
basis. One method to distinguish these differences is the
use of high-density gene expression arrays that will allow
identifying genes specifically implicated in pathological
processes. Much focus has been placed on identifying
gene expression differences between normal ovarian tis-
sue and ovarian cancer to understand the drivers of car-
cinogenesis [3,4]. Several studies have also tried totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient Information used in this study
Age 61 +/− 7
Histology (9 patients) Papillary-serous adenocarcinoma
Grade (9 patients) 3
StageIIICIV (pleural) 81 (OV07-5)
Adjuvant treatment Carboplatin and taxol (6 cycles)
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dictions as well as chemotherapeutic responses [5-7].
These studies have attempted to provide gene predictors
on disease outcome, however, the robustness and repro-
ducibility of these genes lists across different patient
populations have not yet been clearly established or trans-
lated to clinical practice [8]. The question remains, how-
ever, what the genetic requirements are on the primary
tumor cells involved in the progression to metastasis.
Lancaster et al. have compared primary ovarian tumor
and omental metastatic lesions in a study of 20 patients.
They found Fifty-six genes with differential expression be-
tween primary ovarian tumors and omental metastatic
samples. The genes uncovered by their approach were
previously implicated in the metastatic process, cell motil-
ity, migration, and cytoskeletal function. Critical networks
such as the p53 pathway were also enriched [9].
We recently investigated copy number variations
(CNVs) between matched primary and metastatic ovar-
ian tumors [10] and identified large scale differences be-
tween the primary lesions and metastatic lesions and
suggested those changes would likely affect gene expres-
sion as well.
We further hypothesized that gene expression variabil-
ity may be due to the targeting of genomic amplification
or deletion of specific pathways rather than specific
genes themselves. This would result in gene expression
changes that averaged to insignificance when observed
across multiple individuals. However, if gene expression
is considered in the light of copy number variations,
affected pathways relevant to specific patients will more
likely to be identified.
In this follow up study to our analysis of CNVs we
demonstrate transcriptomic differences with potential
therapeutic implication between primary and metastatic
lesions.
Methods
Ethics statement and sample collection/preparation
All the samples were collected in the department of
Gynecologic Oncology at the Institut Claudius Regaud
(DQ, AR, AM, GF). The project was reviewed and
approved by the institution’s Human research Ethics
Committee. All patients included in the study gave
informed written consent prior to surgery. 9 patients
with advance Stage III or IV papillary serous ovarian
adenocarcinoma were prospectively enrolled in this study
at the time of primary surgery before any treatment was
given (Table 1). The patients had a biopsy of the primary
lesion as well as a peritoneal metastasis outside of the
pelvis. In order to ensure very little contamination by the
stromal components the biopsies specifically took the
tumoral nodules without the underlying peritoneal ele-
ments. All biopsies were immediately liquid nitrogensnap frozen. A representative haematoxylin and eosin
stained section from the snap frozen was assessed and
samples with 80% epithelial cells and less than 20% of ne-
crosis (criteria used by the TCGA group [11]) were used
for DNA and RNA extraction from the whole tissue.
RNA and DNA isolation
DNA and RNA were isolated using QIA-cube technol-
ogy as per the manufacturer instructions.
Gene expression arrays
We used the Affymetrix Human Gene 1.0 chip for de-
tection of gene expression levels in this study. The man-
ufacturers protocol for the Affymetrix Human Gene 1.0
chip was strictly followed. 100 ng of total RNA were
used in the analysis.
Data analysis
Gene expression analysis
Data from the Affymetrix Human Gene 1.0 arrays were
analyzed using the PARTEK Genomics Suite software
with recommended normalization (RMA) settings. Com-
parison of gene expression levels between primary tumor
and peritoneal metastasis was conducted using the
paired T-test. Primary ovarian tumors were used as the
baseline in this study. Only genes with at least 1.5 fold
change and paired T-test p-value of less than 0.01 were
reported (Additional file 1: Table 1). A subset with fold
change of 2 is shown in Figure 1. We opted to use a
relatively low cut-off for fold change (1.5 versus the typ-
ical 2 to 3 fold) based on observations from the CNV
data. Specifically, a single allele gain in primary or meta-
static tumors would result in a predicted 1.5 fold change
in gene expression assuming all other factors remained
constant. Additionally, our goal was to use lower signifi-
cance cutoffs yet follow up with more stringent pathway
enrichment analysis. This approach has been shown to
yield significant functional significance despite initial
lack of strong statistical significance [12]. Gene lists from
gene expression were entered into DAVID [13] and
KEGG pathways enriched with Benjamini-Hochberg
score of less than 0.25 were selected.
Overlap of gene expression with copy number variations
Genomics coordinates of Copy Number Variations in
the genomic DNA of matched samples from this study
Ovarian cancer WFDC2, VEGF A, ST14, RAB25, 
IL2RA, IGFBP2, IGF1R, HGF, FOS, 
CAV1 
,7GKN,2MIRT,PINXT,LRDLVsisatsateM
NFATC2, LPXN, DOCK10 
Immune Response TRAT1, SH2D4A 
Proliferation, chemoresistance STK33, SLPI, SGK1, RNF125, 
SH2D4A, RNF125, RGS13, PRKCB, 
PRKAA2, MT2A, MAGI3, ADAM19, 
ABCB1 
Stemness SIX4, PROM1, PIK3CG, MAGI3, 
KLF6, KLF7, GIMAP5, GAS6, CXCR6 
,1GALP,2BCLP,1NSMAS,6nitpeSsrehtO
MAP3K13, KDM5B, KDM3A, CXCL9 
Figure 1 A. Clustering of Tumors based on genes differentially expressed between ovarian primary tumors and their matched
peritoneal metastasis. A fold change cut-off of 2 was used. Normalized Signal intensity levels are plotted for each tumor type at genes
differentially expressed between the tumor types. The Primary tumor was used to create a baseline average. Patient IDs and tumor type are
displayed above the plot. Red: overexpression, Blue:Underexpressed. Ov: ovarian tumor, Pe: peritoneal metastasis. B. List of most relevant genes
associated to neoplasic disease. C. A network representing all genes implicated in the “cancer” category is represented in Figure 1C and
demonstrates the central role of IGF, VEGF, CAV1 and FOS.
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Affymetrix Gene 1.0 chip were mapped to CNVs. Only
those probe sets, representing the whole gene transcript
and which were fully encompassed by a CNV segment
were analyzed. Probe set intensities from the gene ex-
pression analysis for each individual (see above) were
then separated into groups based on amplified, deleted
or normal in a given CNV segment in the respective pa-
tient. Gene expression data for each patient at each gene
was matched to CNV locations. Gene expression data
was then divided into categories at each gene depending
on whether the patient was amplified, deleted or un-
affected in that gene (see Methods). Gene expression
analysis was conducted as CNV segments and a segment
required at least 3 patients’ data within it. For example,all patients showing amplification in a gene had their
matched peritoneum to primary tumor gene expression
differences statistically evaluated through paired T-
tested. Likewise, all patients without a CNV in that same
gene had their matched peritoneum to primary tumor
gene expression differences paired T-tested together.
To detect the overall affect of CNVs on gene expres-
sion we selected all genes within CNVs with expression
differences between peritoneal and primary tumors of at
least 1.32 fold (log2 0.4 or −0.4). This fold change was
used as it is predicted that a single allele amplification or
deletion would result in an approximately 1.5 fold
change of expression. Data was categorized and averaged
by what, if any, copy number variation type it originated
from. The same genes were then analyzed without
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say, all patients’ data was averaged for each gene without
grouping them by copy number variation type. For com-
parison, the results from each analyzed group of amplifi-
cation or deletion was compared to the gene expression
differences in patients with no CNV in that gene.
Gene expression values for primary and metastatic
tumors were normalized in PARTEK using the RMA al-
gorithm. For each gene in a patient's primary/metastatic
pair, the primary tumor expression value was subtracted
from the metastatic expression value. The paired gene
expression differences for all genes in each patient were
then subjected to principal components analysis in PAR-
TEK. The top 3 principal components were plotted in
Figure 2b.Ingenuity pathway analysis
We used Ingenuity Pathway Analysis software (IPA) (In-
genuity Systems, Redwood City, CA) for network ana-
lysis of genes that were differentially regulated between
primary and metastatic lesions. We constructed net-
works by overlaying the up and down regulated genesFigure 2 Pathways enriched in genes differentially expressed betwee
significant targeting of these pathways agrees well with results showing co
and somatic mutations target the Cell-Adhesion pathways.with the gene lists. In the resulting networks genes are
represented as nodes, and biological relationships be-
tween two nodes as lines. All edges are supported by at
least one reference from the literature, textbook, or ca-
nonical information stored in the Ingenuity Pathways
knowledge database. P-values for enrichment of canon-
ical pathways were generated based on the hypergeo-
metric distribution and calculated with the right-tailed
Fisher’s exact for 2 × 2 contingency tables as implemen-
ted in Ingenuity.Results and discussion
Direct comparison of primary and metastatic gene
expression
Using the criteria described in the method section a total
of 299 probe sets representing 266 annotated genes were
differentially expressed in the peritoneal metastases versus
the primary tumors. Of these, 202 genes were over-
expressed and 64 genes were under-expressed in the peri-
toneal metastases versus the primary tumors (Figure 1A
for a subset of these genes and Additional file 1: Table 1).
Some of genes have been previously associated withn peritoneal metastasis and matched primary tumors. The
py number variations target the cytokine-cytokine receptor pathway
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Ingenuity pathway analysis we retrieved an enrichment
in the category “cancer” (25 genes p =1.10-10) as well
as Reproductive System disease (20 genes, p = 1.10-10)
Within the cancer category, “ovarian tumor” was the
most enriched (p = 1.10-10). A network representing all
genes implicated in the “cancer” category is repre-
sented in Figure 1C and demonstrates the central role
of IGF, VEGF, CAV1 and FOS. Functional analysis of
the genes using DAVID [12] revealed that over-
expressed genes were very significantly enriched in
multiple categories. In KEGG pathways, peritoneal
over-expressed genes were enriched in ‘Cell Adhesion
Molecules’ (12 genes, Benjamini-Hochberg (BH)
1.0x10-5), ‘Cytokine-cytokine receptor interaction’ (14
genes, BH score 1.7x10-3) (Figure 3) and ‘Jak-STATFigure 3 Peritoneal Metastasis gene expression of TCGA identified pr
compared to matched tumors for all 9 samples (rows) and gene expression
be prognostic of outcome. Peritoneal metastasis has higher expression of g
when compared to the primary metastasis. Red represents overexpression,
good prognosis and overexpressed in metastasis compared to primary. C.
metastasis compared to primary.signaling pathway’ (8 genes, BH score 0.21) among
others. Gene Ontology analysis revealed very signifi-
cant enrichment for genes with cellular compartment
of ‘Plasma Membrane’ (81 genes, BH score 1.9x10-10).
Likewise, there was very significant enrichment of gene
ontology biological processes of ‘Immune Response’
(48 genes, BH score 8.7x10-24) and cell activation (29
genes, BH score of 2.5x10-17). Interestingly, functional
analysis of the 64 down regulated genes did not show
significant enrichment in any category.
Implication of the metastasis on patients’ prognosis
Recently the TCGA released a large study on ovarian
cancer that included gene expression analysis of 489 pri-
mary tumors [11]. Analysis of the results yielded gene
expression patterns from 193 genes that were prognosticognostic genes. A. Peritoneal metastasis gene expression was
values (columns) were plotted for genes identified by the TCGA to
ood prognostic and lower expression of genes with poor prognosis
blue represents downregulation. B. List of top genes associated to
List of top genes associated to poor prognosis and downregulated in
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mary tumor gene expression differences with relation-
ship to normal tissue, we investigated what the
prognostic gene expression pattern was in metastatic
lesions versus the primary tumor. For the 193 prognostic
genes we recorded gene expression results in the 9 com-
parisons of peritoneal metastasis versus matched pri-
mary tumors. Only genes with detectable expression
levels in all samples were used. There was a significant
level of good prognosis genes being more highly
expressed and poor prognosis genes being lower
expressed in the peritoneal metastasis versus matched
primary tumors (chi-squared test 30.3, 3 d.f., P < 0.0001)
(Figure 4A). This may be indicative of the metastatic
lesions remaining closer to normal tissue in their gene
expression patterns and is an important consideration
when therapies targeting residual disease are considered.
Interestingly, Ingenuity pathway analysis of the most
overexpressed good prognosis genes (Figure 4B)
revealed significant enrichment (more than 5 genes,
p < 0.05) of immune networks including “immune cellu-
lar movement”, “cell mediated immune response”, andFigure 4 The effect of underlying copy number variations on gene ex
Greater than 2000 genes were used for the analysis. When gene expression
(amp), or deletion (del) CNV, the gene expression differences are more sign
(NoSeparation), without separating them based on underlying CNVs, the g
average gene expression differences between primary and peritoneum in g
from patients without CNVs do not change. B. For each gene in a patient's
subtracted from the metastatic expression value. The paired gene expressio
principal components analysis in Partek.“chemoattraction of lymphocytes”. The genes that were
mostly down-regulated in the poor prognosis group
(Figure 4C) were significantly enriched for functions
such as “cellular movement” (chemoattraction of endo-
thelium, migration of cancer cells), “tumor morphology”
(vascularization of tumors) (more than 3 genes,
p < 0.05).
Gene expression analysis guided by CNV analysis
The significant effect of CNVs on level of expressions of
genes located within the CNVs or flanking regions is
well documented [14,15]. Previous observations on the
heterogeneity of ovarian cancer and it’s effect on gene
expression [16] and CNV analysis [10], led us to test the
effect of CNVs on gene expression in ovarian cancer.
Our hypothesis was that underlying heterogeneity in
CNVs is likely a source of gene expression heterogeneity.
In our previous study we had observed specific pathways
consistently affected by CNVs, however, affected genes
within those pathways varied among patients. We there-
fore predicted that accounting for CNVs in the gene ex-
pression data might lead to more accurate understandingpression differences between peritoneal and primary tumors. A.
data is analyzed by groups of patients containing either amplification
ificant (SeparatedByCNV). When patients are all analyzed together
ene expression differences are significantly decreased. As expected, the
enes outside of CNVs (noCNVs) is near zero. Gene expression data
primary/metastatic pair, the primary tumor expression value was
n differences for all genes in each patient were then subjected to
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tially regulated in subsets of patients. We documented
2945 microarray probe sets, representing 2333 annotated
genes, which had both gene expression data for the pa-
tients and which were fully contained within a previously
identified copy number variation for these samples. We
found a very significant effect of underlying copy number
variations on gene expression data (Figure 2A). Specific-
ally, when patients were grouped by CNV type for gene
expression analysis, the gene expression differences were
much more pronounced. As expected, patients with
amplifications in a given gene had significantly higher
expressions levels for that gene and patients with dele-
tions had significantly lower gene expression levels than
did patients with no CNV. Removing the separation of
patient data by CNV significantly reduced the observed
gene expression difference (Figure 2A).Personalized analysis of gene expression
As we discussed above one major drawback of global
gene expression analysis is the averaging that may mask
major differences between patients. Moreover as we be-
lieve that one of the key aspects in ovarian cancer is to
pinpoint the differences between the metastatic lesions
and the primary tumor we attempted to segregate the
metastasis into different groups. One unique aspect of
our dataset is our ability to analyze paired primary and
metastatic lesions. Principal components analysis of the
gene expression differences between pairs of primary
and metastatic tumors showed clear separation in three
groups. These groups followed a similar separation pat-
tern by metastasis age provided in our analysis of the
CNVs [10] demonstrating that some metastasis occur
early with low CNVs compare to HapMap while others
occur late and have numerous CNVs compare to Hap-
Map and are more similar to the primary tumor
(Figure 2B). Specifically, tumors from each metastasis
age category clustered closely to each other and sepa-
rated well from other categories. As expected, tumors
from early metastatic events demonstrated the largest
numbers of differentially expressed genes when com-
pared to the primary tumors. In the early group 804 pro-
besets were up and 1181 probe-sets were downregulated
(> 2 fold change, FDR < 0.2) in metastasis versus primary
tumors (Additional file 2: Table 2). In the mid metastasis
group the number of genes were greatly reduced with
only 89 probe-sets differentially expressed (Additional
file 3: Table 3). In this group the patients tend to have
metastatic lesions that are closer to the primary tumors
as defined by CNV. The increase genomic similarity
induces less transcriptomic differences. In the late me-
tastasis no genes were differentially expressed at a statis-
tically significant level.In order to mimic a personalized approach to this
issue we performed IPA analysis on the gene list
obtained in the early metastasis group. Among the dif-
ferent networks retrieved we focused on the kinase acti-
vation network as predicted by the IPA software.
Interestingly despite the great number of genes in the
global network, the genes implicated in Kinase activation
are quite few (22 genes),(Figure 5 A). These genes were
mainly upregulated in the early metastasis when com-
pared to their primary tumors. Using the same software
we were able to generate a list of drugs able to disrupt
the predicted kinase activation (Figure 5 B).
Conclusions
It is clear from our results that specific pathways in the
peritoneum have both been selected for over-expression
and amplification (or maintenance of normal expression
and avoidance of deletion) with respect to the primary
tumor.. While there appears to be some similar specifi-
city in the deletions and under-expression, the enrich-
ment of pathways was less clear for this category. The
specific targeting of pathways at both the copy number
variation level and the gene expression level in periton-
eal metastasis is, to our knowledge, a novel finding in
EOC. It would seem that CNVs are both a consequence
and cause of gene expression changes. It is likely that
the increased gene expression of these pathways is crit-
ical to survival in the microenvironment as Wang and
colleagues showed that similar pathways are up-
regulated in normal peritoneum of patients with ovarian
cancer versus those with benign conditions [16]. This re-
quirement would disallow deletion of these genes once
the tumor metastasizes to the peritoneum and indeed
may be required for the metastasis to occur. On the
other hand the primary tumor my delete these genes as
they are not required. This has been demonstrated by
others in the case of the chemokine gene CCL2 which is
deleted in 70% of the tumors investigated and heavily
down-regulated in many primary tumors [17]. The study
also reported that loss of heterozygosity (LOH) in the
CCL2 gene was more frequent in advanced tumors than
in earlier stages suggesting it was associated with pro-
gression and not initiation of the cancer. Our combined
gene expression and CNV analysis of CCL2 suggests that
gene expression and copy number are maintained in the
peritoneal metastasis while frequently being deleted in
the matched primary tumors. These differences in CCL2
copy between the primary tumor and metastatic lesions
should help guide the future consideration of che-
motherapeutic targets to avoid targeting primary tumor
specific alterations only. It is interesting to note that ‘Im-
mune Response’ genes, which includes the cytokines,
was heavily enriched in over-expressed genes in the peri-
toneum metastasis. This is unlikely to be solely due to
AB
Figure 5 A. IPA analysis on the gene list obtained in the early metastasis group. Kinase activation network as predicted by the IPA
software. 22 genes implicated in Kinase activation are quite few. B. List of predicted inhibitors disrupting disrupt the predicted kinase activation
network.
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data showed a related enrichment for many of the same
genes. The enrichment for immune response genes was
expansive regardless whether or not CNV data was
taken into account. Indeed, even in 20 ‘immune re-
sponse’ related genes that were deleted in the periton-
eum, gene expression was elevated with respect to the
primary tumor. This indicates that there are likely tran-
scriptional and not just genomic causes for increases
gene expression in this biological process.
As predicted, we did find a significant correlation be-
tween the type of CNV and the effect on gene expression.
This correlation is important for future analysis as typicalgene expression studies seek differential expression of at
least 3 fold. Given our findings, it is likely that there are
many genes whose gene expression is affected by CNVs
but for which the change (approximately 1.5 fold with
gain/loss of single allele) is too small to detect. This may
be the underlying cause of heterogeneity in studies of pri-
mary and metastatic lesions in EOC. When patient sam-
ples are compared simply based on gene expression, the
heterogeneity may result in averaging to insignificance
for a given gene. We have shown that, by analyzing gene-
expression data in light of CNV data, we recover more
differentially expressed genes reported by previous stud-
ies. This is especially true in the case of metastases that
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their later counterparts. This approach will be critical in
truly identifying pathways rather than specific genes that
are targeted in ovarian cancer metastasis.
Along these lines, our analysis of the early metastasis
group revealed a network of kinases with existing che-
motherapeutic agents. This method of individually
studying patients’ metastases should lead to a more ef-
fective, personalized medicine. The identification of dif-
ferences between metastatic and primary tumors leads
to two concepts: (i) differences between the metastasis
and primary tumors will require therapies targeting their
specific genetic alterations [18,19]; (ii) It becomes critical
to focus significant research on metastatic disease, and
several important aspects remain to be addressed such
as: levels of heterogeneity of metastatic lesions within
the same patient, and the biology of recurrent or re-
sidual disease compared to the primary and metastatic
disease.
Answering these primordial questions in ovarian can-
cer will help us design personalized approaches to the
disease using a more targeted and comprehensive ap-
proach than the analysis of the primary tumor alone.
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